Disruptive Strategies for Removing Drug Discovery Bottlenecks

Sean Ekins, Chris Waller, Mary Bradley, Antony Williams
  • Nature Precedings, March 2012, Springer Science + Business Media
  • DOI: 10.1038/npre.2012.6961

drug discovery bottlenecks

What is it about?

Drug Discovery is shifting focus from the industry to outside partners and in the process creating new bottlenecks, suggesting the need for a more disruptive overhaul. We suggest there needs to be an awareness of what research is going on in the academic screening centers, more collaboration and coordination. These efforts will shift the focus to finding the best researchers to fund and require a rethink of how to reward their collaborative efforts.

Why is it important?

his opinion was later expanded and published by DDT. The emphasis here was using computational approaches to predict safety and efficacy.

Perspectives

Dr Sean Ekins (Author)
Collaborations in Chemistry

This publication was one of my earliest experiments in prepublication. Nature Precedings closed soon after in 2012. I personally think this was a mistake to close it http://precedings.nature.com/ and perhaps others benefited from this. Additional experiments in this area include using Figshare recently to post preprints as well as publishing in F1000Research.

Read Publication

http://dx.doi.org/10.1038/npre.2012.6961

The following have contributed to this page: Dr Sean Ekins and Dr Antony John Williams